Skip to content

8:00 am Registration & Morning Coffee

8:50 am Chairperson Opening Remarks

Establishing a Gold Standard for Bacteriophage Therapy Clinical Trials

9:00 am Moving Clinical Trials for Phage Therapy Forward: Maximizing the Likelihood for Informative and Significant Trials

9:30 am Phage Therapy Treatment of Acne and Other Chronic Diseases

10:00 am Microbiology Support for Phage Therapy Trials: The Devils in the Details

  • Daniel Stahm VP, Global Microbiology Services & CSO, International Health Management Associates

10:30 am Morning Refreshments & Networking

11:00 am Single-Molecule Long-Read Sequencing of Phage Mutational Landscape

Resisting Resistance: Ensuring Bacteriophage Is a Long-Term Viable Treatment Option

11:15 am Ensuring Phage is a Long-Term Viable Treatment Option

  • Greg Merril Co-Founder & CEO , Adaptive Phage Therapeutics

11:45 am Development of Lysins for the Treatment of Multidrug Resistant Bacterial Infections

12:15 pm Engineering Phages to Widen Their Host Range To Overcome Bacterial Resistance Through Tail Fiber Mutagenesis

  • Kevin Yehl Postdoctoral Research Associate, Massachusetts Institute of Technology

12:45 pm Lunch & Networking

Where is Phage Therapy Heading?

2:00 pm Delivery of Therapeutic DNA Payloads via Phage-Derived Vectors

2:30 pm Bacterial Cybergenetics: Resurrecting Sensitivity to Antibiotics in Anti-Microbial Resistant Bacteria

3:00 pm Delivery of Phage-Based Drugs, and Their Incorporation in Medical Devices

3:30 pm Afternoon Refreshments & Networking

Optimizing Phage Discovery and Treatment through Advances in Technology

4:00 pm Precision Biofilm Disruption and Vaginome Editing with Phage-Based Drug Candidates

4:30 pm How Can Genome Sequencing Be Used to Identify Functionally Useful Bacteriophage Characteristics to Select Phages for Appropriate Production?

5:00 pm Chairperson Closing Remarks

5:10 pm Close of Conference Day Two